Chardan Capital Maintains Buy on 4D Molecular Therapeutics, Raises Price Target to $26
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
Chardan Capital analyst Geulah Livshits maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and raises the price target from $25 to $26.
Chardan Capital analyst Geulah Livshits maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Buy and raises the price target from $25 to $26.